We are using cookies to implement functions like login, shopping cart or language selection for this website. Furthermore we use Google Analytics to create anonymized statistical reports of the usage which creates Cookies too. You will find more information in our privacy policy.
OK, I agree I do not want Google Analytics-Cookies
International Journal of Oral Implantology
Login:
username:

password:

Plattform:

Forgotten password?

Registration

Int J Oral Implantol 5 (2012), No. 2     2. Aug. 2012
Int J Oral Implantol 5 (2012), No. 2  (02.08.2012)

Page 165-173, PubMed:22866292


Efficacy of quick-release lornoxicam versus placebo for acute pain management after dental implant surgery: a randomised placebo-controlled triple-blind trial
Bölükbasi, Nilüfer / Ersanli, Selim /Basegmez, Cansu / Özdemir, Tayfun / Özyalcin, Süleyman
Aim: To assess the efficacy of quick-release lornoxicam (LNX) on patient-reported acute pain after dental implant surgery.
Materials and methods: The study included subjects in good general health, aged 18 to 65 and scheduled to receive a maximum of three implants in the same quadrant. Participants received either 8 mg LNX or placebo and were asked to use the medications in case of pain in the first 120 min after implant surgery. Assessment of efficacy was performed using self-assessment questionnaires for the evaluation of pain intensity and pain relief for 12 h post dosing. Patients were also asked to record the rescue analgesic number. Evaluation of patient satisfaction was assessed using a 7-point scale. Safety was evaluated by the incidence of adverse events.
Results: A total of 83 (LNX/placebo, 42/41) patients who met the inclusion criteria and finished the evaluation period were included in the study. The proportion of patients experiencing postoperative pain was significantly lower in the LNX-treated group compared to the placebo group. Patients in the LNX group reported significantly higher pain relief scores than the placebo group. Twenty-nine patients in the placebo group and 6 patients in the LNX group used rescue analgesics. The number of used rescue analgesics was 1.024 ± 0.79 and 0.167 ± 0.43 in the placebo and LNX groups, respectively. The level of patient satisfaction was significantly higher in the LNX-treated patients (P = 0.007). No adverse events were reported during the study period.
Conclusions: Quick-release LNX is effective in postoperative acute pain control and has a high safety profile following dental implant surgery.

Keywords: dental implant, lornoxicam, NSAIDs, pain